maclizumab-dexamethasone conjugate (Cytoguide)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namemaclizumab-dexamethasone conjugate (Cytoguide)
Drug Alias NameCymac-001Maclizumab (Cytoguide)Maclizumab (Cytoguide)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionGlucocorticoid receptor agonistsScavenger receptor cysteine-rich type 1 protein M130 modulatorsPhospholipases A2 inhibitors
TargetsGlucocorticoid receptorPhospholipases A2Scavenger receptor cysteine-rich type 1 protein M130
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCytoguide ApS
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCytoguide ApSAffinicon ApS
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A